<?xml version='1.0' encoding='utf-8'?>
<document id="30479172"><sentence text="Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation." /><sentence text="Letermovir is a new antiviral approved to prevent cytomegalovirus infection in hematopoietic stem cell transplant recipients"><entity charOffset="0-10" id="DDI-PubMed.30479172.s2.e0" text="Letermovir" /></sentence><sentence text=" It has a distinct mechanism of action as it acts as a terminase complex inhibitor, and shows some advantages compared to the current treatment options for cytomegalovirus infection" /><sentence text=" Areas covered: This review focuses on the efficacy, safety, pharmacokinetics, pharmacodynamics, and drug-drug interactions of letermovir" /><sentence text=" Expert opinion: Letermovir is a new antiviral to prevent cytomegalovirus infection" /><sentence text=" Unlike the currently used polymerase inhibitors, it has a distinct mechanism of action with better safety, limited resistance, and no cross-resistance" /><sentence text=" Although a lot of research on pharmacokinetics and drug-drug interactions has already been performed, it might be useful to clarify the effect of letermovir on voriconazole exposure, the drug-drug interaction between caspofungine and letermovir and the effect of statins on letermovir exposure"><entity charOffset="161-173" id="DDI-PubMed.30479172.s7.e0" text="voriconazole" /><entity charOffset="218-230" id="DDI-PubMed.30479172.s7.e1" text="caspofungine" /><pair ddi="false" e1="DDI-PubMed.30479172.s7.e0" e2="DDI-PubMed.30479172.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30479172.s7.e0" e2="DDI-PubMed.30479172.s7.e1" /></sentence><sentence text=" Also, the lack of an exposure-response relationship should be confirmed in large real-life post-marketing studies in order to be able to lower the intravenous dose of letermovir" /><sentence text="" /></document>